|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Department of Internal Medicine; and Division of Allergy and Immunology, St. Louis University Health Sciences Center
2 From the Department of Pediatrics; and Division of Allergy and Immunology, St. Louis University Health Sciences Center
3 From the Department of Pediatrics; and Division of Pulmonology, St. Louis University Health Sciences Center
Study objective: The object of the study was to longitudinally follow immune parameters of Aspergillus fumigatus sensitization so as to predict those at risk for developing allergic bronchopulmonary aspergillosis (ABPA).
Design: Patients were evaluated for 5 immune parameters (skin test [ST], positive precipitating antibody [PPN], total IgE, IgE anti-A fumigatus antibody [IgE-Af], and IgG anti-A fumigatus antibody [IgG-Af]) at yearly intervals over a 12-year time period.
Setting: Patients were enrolled and evaluated during routine visits to the cystic fibrosis (CF) clinic at Cardinal Glennon Children's Hospital, St. Louis.
Patients: One hundred eighteen patients with documented CF participated.
Interventions: None.
Measurements and results: Six patients were diagnosed as having ABPA. In the non-ABPA patient group, 42% had a positive ST, 42% were PPN positive, 54% had IgE-Af, 61% had IgG-Af, and 10% had an IgE greater than 1,000 IU/mL at some point in time. However, on follow-up, 18% lost skin reactivity, 54% lost PPN, 53% lost IgE-Af, 45% lost IgG-Af, and IgE greater than 1,000 IU/mL declined more than 72% in 64% patients. These losses were spontaneous, without systemic corticosteroid intervention.
Conclusions: Spontaneous diminution and loss of immune parameters in non-ABPA CF patients prevented us from defining a profile of sensitivity likely to result in ABPA. This variability highlights the importance of obtaining follow-up studies and including clinical symptoms when considering the diagnosis of ABPA in patients with CF.
Key Words: allergic sensitization aspergillosis Aspergillus cystic fibrosis
Submitted on February 6, 1995
Accepted on March 13, 1996
This article has been cited by other articles:
![]() |
D. Shoseyov, K. G. Brownlee, S. P. Conway, and E. Kerem Aspergillus bronchitis in cystic fibrosis. Chest, July 1, 2006; 130(1): 222 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Geller, H. Kaplowitz, M. J. Light, and A. A. Colin Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: Reported Prevalence, Regional Distribution, and Patient Characteristics Chest, September 1, 1999; 116(3): 639 - 646. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Latge Aspergillus fumigatus and Aspergillosis Clin. Microbiol. Rev., April 1, 1999; 12(2): 310 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. B. Nepomuceno, S. Esrig, and R. B. Moss Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: Role of Atopy and Response to Itraconazole Chest, February 1, 1999; 115(2): 364 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gondor, M. G. Michaels, and J. D. Finder Non-Aspergillus Allergic Bronchopulmonary Mycosis in a Pediatric Patient With Cystic Fibrosis Pediatrics, December 1, 1998; 102(6): 1480 - 1482. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |